158 related articles for article (PubMed ID: 24060487)
1. Exploring the molecular determinants of substrate-selective inhibition of cyclooxygenase-2 by lumiracoxib.
Windsor MA; Valk PL; Xu S; Banerjee S; Marnett LJ
Bioorg Med Chem Lett; 2013 Nov; 23(21):5860-4. PubMed ID: 24060487
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.
Blobaum AL; Marnett LJ
J Biol Chem; 2007 Jun; 282(22):16379-90. PubMed ID: 17434872
[TBL] [Abstract][Full Text] [Related]
3. Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone.
Orlando BJ; Malkowski MG
J Biol Chem; 2016 Jul; 291(29):15069-81. PubMed ID: 27226593
[TBL] [Abstract][Full Text] [Related]
4. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2.
Duggan KC; Hermanson DJ; Musee J; Prusakiewicz JJ; Scheib JL; Carter BD; Banerjee S; Oates JA; Marnett LJ
Nat Chem Biol; 2011 Nov; 7(11):803-9. PubMed ID: 22053353
[TBL] [Abstract][Full Text] [Related]
5. Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors.
Bertinaria M; Shaikh MA; Buccellati C; Cena C; Rolando B; Lazzarato L; Fruttero R; Gasco A; Hoxha M; Capra V; Sala A; Rovati GE
ChemMedChem; 2012 Sep; 7(9):1647-60. PubMed ID: 22865828
[TBL] [Abstract][Full Text] [Related]
6. Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
Felden L; Walter C; Angioni C; Schreiber Y; von Hentig N; Ferreiros N; Geisslinger G; Lötsch J
Pharm Res; 2014 Jul; 31(7):1813-22. PubMed ID: 24469906
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of new nicotinate derivatives as potential anti-inflammatory agents targeting COX-2 enzyme.
El-Dash Y; Khalil NA; Ahmed EM; Hassan MSA
Bioorg Chem; 2021 Feb; 107():104610. PubMed ID: 33454504
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor.
Rordorf CM; Choi L; Marshall P; Mangold JB
Clin Pharmacokinet; 2005; 44(12):1247-66. PubMed ID: 16372823
[TBL] [Abstract][Full Text] [Related]
9. Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo.
Klein T; Dullweber F; Brehm C; Prinz W; Baudler M; Figala V; Herrmann M
Biochem Pharmacol; 2008 Sep; 76(6):717-25. PubMed ID: 18674517
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R; Azizi E; Daraie B; Hedayati M; Dadrass OG
Bioorg Med Chem; 2009 Jul; 17(14):5312-7. PubMed ID: 19560931
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.
Ghodsi R; Zarghi A; Daraei B; Hedayati M
Bioorg Med Chem; 2010 Feb; 18(3):1029-33. PubMed ID: 20061161
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
Bannwarth B; Berenbaum F
Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of a radioiodinated lumiracoxib derivative for the imaging of cyclooxygenase-2 expression.
Kuge Y; Obokata N; Kimura H; Katada Y; Temma T; Sugimoto Y; Aita K; Seki K; Tamaki N; Saji H
Nucl Med Biol; 2009 Nov; 36(8):869-76. PubMed ID: 19875043
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R
Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: An integrated study.
Atherton C; Jones J; McKaig B; Bebb J; Cunliffe R; Burdsall J; Brough J; Stevenson D; Bonner J; Rordorf C; Scott G; Branson J; Hawkey CJ
Clin Gastroenterol Hepatol; 2004 Feb; 2(2):113-20. PubMed ID: 15017615
[TBL] [Abstract][Full Text] [Related]
16. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: identification of multiple quinone imine intermediates and GSH adducts.
Kang P; Dalvie D; Smith E; Renner M
Chem Res Toxicol; 2009 Jan; 22(1):106-17. PubMed ID: 19063590
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
Selg E; Buccellati C; Andersson M; Rovati GE; Ezinga M; Sala A; Larsson AK; Ambrosio M; Låstbom L; Capra V; Dahlén B; Ryrfeldt A; Folco GC; Dahlén SE
Br J Pharmacol; 2007 Dec; 152(8):1185-95. PubMed ID: 17965743
[TBL] [Abstract][Full Text] [Related]
19. Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2.
Blobaum AL; Xu S; Rowlinson SW; Duggan KC; Banerjee S; Kudalkar SN; Birmingham WR; Ghebreselasie K; Marnett LJ
J Biol Chem; 2015 May; 290(20):12793-803. PubMed ID: 25825493
[TBL] [Abstract][Full Text] [Related]
20. Effect of selective cyclooxygenase-2 inhibitor lumiracoxib on phenolsulfonphthalein disposition in rats.
Honjo H; Uwai Y; Nabekura T
Drug Metabol Drug Interact; 2014; 29(3):203-6. PubMed ID: 24870608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
